Base de dados : MEDLINE
Pesquisa : G12.450.050.420 [Categoria DeCS]
Referências encontradas : 4224 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 423 ir para página                         

  1 / 4224 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29314175
[Au] Autor:Cohn M
[Ad] Endereço:Conceptual Immunology Group, The Salk Institute, La Jolla, CA, USA.
[Ti] Título:Somatic diversification of the B cell repertoire requires two cell subsets.
[So] Source:Scand J Immunol;87(3), 2018 Mar.
[Is] ISSN:1365-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Evolution found itself in a Catch-22 situation when selecting for the somatically derived paratopic repertoire of the humoral immune system. The B cell BCR repertoire can only be somatically diversified from a substrate of paratopes that is encoded in the germline. In order for the cells expressing that substrate to also be a target of germline selection, their BCRs must, independently, be of selective value by being expressed in a functionally important way in each individual. A somatically derived repertoire scrambles this substrate so that its specificities are lost, making it unselectable in the germline. Consequently, evolution faced an incompatibility. Here, we explore what it takes to resolve it.
[Mh] Termos MeSH primário: Subpopulações de Linfócitos B/citologia
Sítios de Ligação de Anticorpos/imunologia
Diferenciação Celular/imunologia
Região Variável de Imunoglobulina/imunologia
Anticorpos de Domínio Único/imunologia
[Mh] Termos MeSH secundário: Anticorpos/imunologia
Subpopulações de Linfócitos B/imunologia
Linhagem da Célula/imunologia
Genes de Imunoglobulinas
Seres Humanos
Imunidade Humoral/imunologia
Região Variável de Imunoglobulina/genética
Anticorpos de Domínio Único/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Immunoglobulin Variable Region); 0 (Single-Domain Antibodies)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12640


  2 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465179
[Au] Autor:Mullaivanam Ramasamy S; Denis M; Sivakumar S; Munusamy A
[Ad] Endereço:Laboratory of Pathobiology, Department of Zoology, University of Madras, Guindy Campus, Chennai 600 025, Tamil Nadu, India. Electronic address: sivakumarmr1981@gmail.com.
[Ti] Título:Phenoloxidase activity in humoral plasma, hemocyanin and hemocyanin separated proteins of the giant freshwater prawn Macrobrachium rosenbergii.
[So] Source:Int J Biol Macromol;102:977-985, 2017 Sep.
[Is] ISSN:1879-0003
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Hemocyanin is a copper containing protein and its role in the immune function of phenoloxidase (PO) activity was investigated in the giant freshwater prawn Macrobrachium rosenbergii. Hemocyanin, sedimented by ultracentrifugation from the plasma appeared on polyacrylamide gel electrophoresis (PAGE 7%) on Coomassie Brilliant Blue and bathocuproine sulfonic acid stain as four copper containing proteins of molecular masses 50, 60, 114 and 325kDa. Accordingly, on diethylaminoethyl-cellulose anion exchange column hemocyanin separated into four proteins designated as MrHc1, MrHc2, MrHc3 and MrHc4 with electrophoretically (PAGE) determined molecular masses of 60, 114, 50 and 325kDa respectively. The reduction of proteins in sodium dodecyl sulphate (SDS)-PAGE revealed that MrHc1 and 3 were monomeric for 60and 50kDa respectively, MrHc2 dimeric of 56 and 58kDa subunits and MrHc4 appeared with three subunits of 74, 76 and 78kDa. The PO activity was determined in plasma, hemocyanin and the four separated hemocyanin proteins in vitro using L-3,4-dihydroxyphenylalanine (L-DOPA) at pH7.5, 25°C and appeared elicited by exogenous activators such as trypsin, SDS, cell wall components of bacteria and polysaccharide laminarin. This study clearly demonstrated hemocyanin as the major copper containing protein in the plasma of M. rosenbergii with potent PO activity.
[Mh] Termos MeSH primário: Hemocianinas/metabolismo
Imunidade Humoral
Monofenol Mono-Oxigenase/sangue
Monofenol Mono-Oxigenase/metabolismo
Palaemonidae/enzimologia
[Mh] Termos MeSH secundário: Animais
Palaemonidae/imunologia
Palaemonidae/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9013-72-3 (Hemocyanins); EC 1.14.18.1 (Monophenol Monooxygenase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  3 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28455172
[Au] Autor:Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
[Ad] Endereço:Department of Pediatrics, Universidad del Valle and Centro de Estudios en Infectología Pediátrica, Cali, Colombia.
[Ti] Título:Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
[So] Source:Vaccine;35(28):3591-3597, 2017 06 16.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufacturers. METHODS: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study groups received three doses of bOPV at 6, 10 and 14weeks and either one IPV dose at 14weeks (groups SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36weeks (groups SP-2, GSK-2 and BBio-2) from three different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40weeks (two IPV doses) and stools were collected weekly for 4weeks to assess viral shedding. Serum neutralizing antibodies were measured at various time points pre and post vaccination. Serious adverse events and important medical events (SAE and IME) were monitored for 6months after last study vaccine. RESULTS: At week 18, 4weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4% and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were seronegative before IPV administration. At 40weeks, 4weeks after a second IPV dose, type 2 seroconversion rates were ≥99% for any of the three manufacturers. There were no significant differences in fecal shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1-2.6]); GSK: 2.2 [1.7-2.5]; BBio 1.8 [1.5-2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME. CONCLUSION: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal immunity after one or two doses. The parent study was registered with ClinicalTrials.gov, number NCT01831050.
[Mh] Termos MeSH primário: Esquemas de Imunização
Imunogenicidade da Vacina
Vacina Antipólio de Vírus Inativado/efeitos adversos
Vacina Antipólio de Vírus Inativado/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/sangue
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Fezes/virologia
Feminino
Seres Humanos
Imunidade Humoral
Lactente
Intestinos/imunologia
América Latina
Masculino
Poliomielite/prevenção & controle
Vacina Antipólio de Vírus Inativado/administração & dosagem
Vacina Antipólio Oral/administração & dosagem
Vacina Antipólio Oral/efeitos adversos
Vacina Antipólio Oral/imunologia
Soroconversão
Vacinação
Eliminação de Partículas Virais
Organização Mundial da Saúde
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Poliovirus Vaccine, Inactivated); 0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  4 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455171
[Au] Autor:Moberley S; Licciardi PV; Balloch A; Andrews R; Leach AJ; Kirkwood M; Binks P; Mulholland K; Carapetis J; Tang MLK; Skull S
[Ad] Endereço:Menzies School of Health Research, Child Health Division, Charles Darwin University, Northern Territory, Australia.
[Ti] Título:Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.
[So] Source:Vaccine;35(22):2908-2915, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Indigenous adults residing in the Northern Territory of Australia experience elevated rates of invasive pneumococcal disease despite the routine use of 23-valent pneumococcal polysaccharide vaccine (23vPPV). We hypothesised that the limited protection from 23vPPV may be due to hyporesponsiveness as a result of vaccine failure from repeated vaccination. To explore this possibility, we evaluated the immune response to a first and second dose of 23vPPV in Indigenous adults and a first dose of 23vPPV in non-Indigenous adults. METHODS: Serotype-specific IgG was measured by ELISA for all 23 vaccine serotypes at baseline and at one month post-vaccination. Individuals were considered to have an adequate immune response if paired sera demonstrated either: a four-fold rise in antibody concentration; a two-fold rise if the post vaccination antibody was >1.3µg/ml but <4.0µg/ml; or a post-vaccination antibody concentration >4.0µg/ml for at least half of the serotypes tested (12/23). Our per-protocol analysis included the comparison of outcomes for three groups: Indigenous adults receiving a second 23vPPV dose (N=20) and Indigenous (N=60) and non-Indigenous adults (N=25) receiving their first 23vPPV dose. RESULTS: All non-Indigenous adults receiving a first dose of 23vPPV mounted an adequate immune response (25/25). There was no significant difference in the proportion of individuals with an adequate response using our definition (primary endpoint), with 88% of Indigenous adults mounted an adequate response following first dose 23vPPV (53/60) compared to 70% having an adequate response following a second dose of 23vPPV (14/20; p=0.05). The risk difference between Indigenous participants receiving first dose compared to non-Indigenous participants receiving first dose was significant when comparing a response threshold of at least 70% (-27%, 95% CI: -43% to -11%; p=0.01) and 90% (-38%, 95% CI: -60% to -16%; p=0.006) of serotypes with a positive response. CONCLUSION: Indigenous participants demonstrated a poorer response to a first dose 23vPPV compared to their non-Indigenous counterparts, with lower IgG following a second 23vPPV dose. These findings highlight the critical need to evaluate the efficacy of future pneumococcal vaccine programs in the Australian Indigenous populations that recommend repeated doses of 23vPPV.
[Mh] Termos MeSH primário: Imunidade Humoral
Imunogenicidade da Vacina
Grupo com Ancestrais Oceânicos
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas/imunologia
Streptococcus pneumoniae/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Antibacterianos/sangue
Feminino
Seres Humanos
Imunoglobulina G/sangue
Masculino
Meia-Idade
Northern Territory/epidemiologia
Infecções Pneumocócicas/etnologia
Infecções Pneumocócicas/imunologia
Infecções Pneumocócicas/microbiologia
Vacinas Pneumocócicas/administração & dosagem
Vacinas Pneumocócicas/efeitos adversos
Sorotipagem
Vacinação
Potência de Vacina
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (23-valent pneumococcal capsular polysaccharide vaccine); 0 (Antibodies, Bacterial); 0 (Immunoglobulin G); 0 (Pneumococcal Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  5 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449972
[Au] Autor:Sil A; Ravi MD; Patnaik BN; Dhingra MS; Dupuy M; Gandhi DJ; Dhaded SM; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Rout SP; Jayanth MV; D'Cor NA; Mangarule SA; Ravinuthala S; Reddy E J
[Ad] Endereço:Shantha Biotechnics Private Limited - A Sanofi Company, Hyderabad, India. Electronic address: arijit.sil@sanofi.com.
[Ti] Título:Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.
[So] Source:Vaccine;35(22):2999-3006, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vaccination is considered as the most cost effective method for preventing infectious diseases. Low grade fever is a known adverse effect of vaccination. In India, it is a common clinical practice to prescribe paracetamol either prophylactically or therapeutically to manage fever. Some studies have shown that paracetamol interferes with antibody responses following immunization. This manuscript reports the outcome of a post hoc analysis of data from a clinical trial of a pentavalent vaccine in Indian infants where paracetamol was not used or was used either as prophylaxis or for treatment of fever. METHODS: Pre and post vaccine antibody levels against Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type B were assessed in no paracetamol and paracetamol groups. The paracetamol group was further divided into prophylactic and treatment groups. RESULTS: Similar rates of seroprotection/seroresponse for anti-D, anti-T, anti-wP, anti-PT, anti-HBs and anti-PRP were observed in all the groups. There was no clear tendency for difference in percentage seroprotection/seroresponse and geometric mean (GM) titers in any of the groups. CONCLUSION: The study found no evidence that paracetamol usage either as prophylactic or for treatment impact immunological responses to DTwP-HepB-Hib combination vaccine. [Clinical trial registry of India (study registration number CTRI/2012/08/002872)].
[Mh] Termos MeSH primário: Acetaminofen/uso terapêutico
Anticorpos Antibacterianos/sangue
Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem
Vacina contra Difteria, Tétano e Coqueluche/imunologia
Vacinas Anti-Haemophilus/administração & dosagem
Vacinas Anti-Haemophilus/imunologia
Vacinas contra Hepatite B/administração & dosagem
Vacinas contra Hepatite B/imunologia
Imunidade Humoral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acetaminofen/administração & dosagem
Acetaminofen/efeitos adversos
Difteria/imunologia
Difteria/prevenção & controle
Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos
Feminino
Febre/tratamento farmacológico
Febre/etiologia
Febre/prevenção & controle
Infecções por Haemophilus/etnologia
Infecções por Haemophilus/imunologia
Infecções por Haemophilus/prevenção & controle
Vacinas Anti-Haemophilus/efeitos adversos
Hepatite B/imunologia
Hepatite B/prevenção & controle
Anticorpos Anti-Hepatite B/sangue
Vacinas contra Hepatite B/efeitos adversos
Seres Humanos
Índia
Lactente
Masculino
Tétano/imunologia
Tétano/prevenção & controle
Vacinação
Vacinas Conjugadas/imunologia
Coqueluche/imunologia
Coqueluche/prevenção & controle
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Diphtheria-Tetanus-Pertussis Vaccine); 0 (DtwP-HepB-Hib vaccine); 0 (Haemophilus Vaccines); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Vaccines); 0 (Vaccines, Conjugate); 362O9ITL9D (Acetaminophen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  6 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28742815
[Au] Autor:Xu J; Guardado J; Hoffman R; Xu H; Namas R; Vodovotz Y; Xu L; Ramadan M; Brown J; Turnquist HR; Billiar TR
[Ad] Endereço:Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
[Ti] Título:IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model.
[So] Source:PLoS Med;14(7):e1002365, 2017 Jul.
[Is] ISSN:1549-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The immunosuppression and immune dysregulation that follows severe injury includes type 2 immune responses manifested by elevations in interleukin (IL) 4, IL5, and IL13 early after injury. We hypothesized that IL33, an alarmin released early after tissue injury and a known regulator of type 2 immunity, contributes to the early type 2 immune responses after systemic injury. METHODS AND FINDINGS: Blunt trauma patients admitted to the trauma intensive care unit of a level I trauma center were enrolled in an observational study that included frequent blood sampling. Dynamic changes in IL33 and soluble suppression of tumorigenicity 2 (sST2) levels were measured in the plasma and correlated with levels of the type 2 cytokines and nosocomial infection. Based on the observations in humans, mechanistic experiments were designed in a mouse model of resuscitated hemorrhagic shock and tissue trauma (HS/T). These experiments utilized wild-type C57BL/6 mice, IL33-/- mice, B6.C3(Cg)-Rorasg/sg mice deficient in group 2 innate lymphoid cells (ILC2), and C57BL/6 wild-type mice treated with anti-IL5 antibody. Severely injured human blunt trauma patients (n = 472, average injury severity score [ISS] = 20.2) exhibited elevations in plasma IL33 levels upon admission and over time that correlated positively with increases in IL4, IL5, and IL13 (P < 0.0001). sST2 levels also increased after injury but in a delayed manner compared with IL33. The increases in IL33 and sST2 were significantly greater in patients that developed nosocomial infection and organ dysfunction than similarly injured patients that did not (P < 0.05). Mechanistic studies were carried out in a mouse model of HS/T that recapitulated the early increase in IL33 and delayed increase in sST2 in the plasma (P < 0.005). These studies identified a pathway where IL33 induces ILC2 activation in the lung within hours of HS/T. ILC2 IL5 up-regulation induces further IL5 expression by CXCR2+ lung neutrophils, culminating in early lung injury. The major limitations of this study are the descriptive nature of the human study component and the impact of the potential differences between human and mouse immune responses to polytrauma. Also, the studies performed did not permit us to make conclusions about the impact of IL33 on pulmonary function. CONCLUSIONS: These results suggest that IL33 may initiate early detrimental type 2 immune responses after trauma through ILC2 regulation of neutrophil IL5 production. This IL33-ILC2-IL5-neutrophil axis defines a novel regulatory role for ILC2 in acute lung injury that could be targeted in trauma patients prone to early lung dysfunction.
[Mh] Termos MeSH primário: Regulação da Expressão Gênica
Imunidade Humoral
Interleucina-33/metabolismo
Interleucina-5/genética
Linfócitos/imunologia
Ferimentos e Lesões/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Animais
Estudos de Coortes
Modelos Animais de Doenças
Feminino
Seres Humanos
Interleucina-33/sangue
Interleucina-5/imunologia
Pulmão/imunologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Meia-Idade
Estudos Retrospectivos
Choque Hemorrágico/complicações
Choque Hemorrágico/imunologia
Ferimentos e Lesões/etiologia
Ferimentos e Lesões/genética
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (IL33 protein, human); 0 (Il33 protein, mouse); 0 (Interleukin-33); 0 (Interleukin-5)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pmed.1002365


  7 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456076
[Au] Autor:Yang Z; Xu M; Jia Z; Zhang Y; Wang L; Zhang H; Wang J; Song M; Zhao Y; Wu Z; Zhao L; Yin Z; Hong Z
[Ad] Endereço:National Key Laboratory of Medical Chemical Biology & Tianjin Key Laboratory of Protein Science, Nankai University, Tianjin, 300071, China.
[Ti] Título:A novel antigen delivery system induces strong humoral and CTL immune responses.
[So] Source:Biomaterials;134:51-63, 2017 Jul.
[Is] ISSN:1878-5905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:New strategies with the ability to enhance both the humoral and cellular immune responses remain a priority for the development of future therapeutic cancer vaccines. In this study, we took advantage of ß-glucan particles (GPs) derived from Saccharomyces cerevisiae baker's yeast and a novel reverse micro-emulsion method to prepare an antigen-loaded GP carrier system for dendritic cell (DC) specific antigen delivery, followed by careful evaluation of the immune functions of the prepared particles in initiating both the humoral and cellular immune responses through in vitro and in vivo experiments. The prepared particles greatly promoted DC activation and cytokine production and cross presented the antigen to CD8 cells, inducing very strong OVA specific humoral and cellular immune responses. Treatment with these particles significantly prevented the growth of implanted EG7-OVA tumors in a prophylactic and pre-established tumor model. These results suggest that our strategy may be able to be utilized as a promising platform for cancer immunotherapy.
[Mh] Termos MeSH primário: Imunidade Celular/fisiologia
Imunidade Humoral/fisiologia
Neoplasias/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos/administração & dosagem
Antígenos/imunologia
Vacinas Anticâncer/imunologia
Células Dendríticas/imunologia
Imunoterapia/métodos
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens); 0 (Cancer Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  8 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29360858
[Au] Autor:Zhang A; Yang X; Li Q; Yang Y; Zhao G; Wang B; Wu D
[Ad] Endereço:Xinjiang Key Lab of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China.
[Ti] Título:Immunostimulatory activity of water-extractable polysaccharides from Cistanche deserticola as a plant adjuvant in vitro and in vivo.
[So] Source:PLoS One;13(1):e0191356, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A safe and effective vaccine adjuvant is important in modern vaccines. Various Chinese herbal polysaccharides can activate the immune system. Cistanche deserticola (CD) is a traditional Chinese herb and an adjuvant candidate. Here, we confirmed that water-extractable polysaccharides of CD (WPCD) could modulate immune responses in vitro and in vivo. In a dose-dependent manner, WPCD significantly promoted the maturation and function of murine marrow-derived dendritic cells (BM-DCs) through up-regulating the expression levels of MHC-II, CD86, CD80, and CD40, allogenic T cell proliferation, and the yields of IL-12 and TNF-α via toll-like receptor4 (TLR4), as indicated by in vitro experiments. In addition, its immunomodulatory activity was also observed in mice. WPCD effectively improved the titers of IgG, IgG1 and IgG2a and markedly enhanced the proliferation of T and B cells, the production of IFN-γ and IL-4 in CD4+ T cells and the expression level of IFN-γ in CD8+ T cells better than Alum. Furthermore, WPCD could markedly up-regulate the expression levels of CD40 and CD80 on DCs in spleen and down-regulate the Treg frequency. The study suggests that polysaccharides of Cistanche deserticola are a safe and effective vaccine adjuvant for eliciting both humoral immunity and cellular immunity by activating DCs via TLR4 signaling pathway.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Cistanche/química
Polissacarídeos/farmacologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Adjuvantes Imunológicos/isolamento & purificação
Animais
Diferenciação Celular/efeitos dos fármacos
Células Dendríticas/citologia
Células Dendríticas/efeitos dos fármacos
Células Dendríticas/imunologia
Medicamentos de Ervas Chinesas/administração & dosagem
Medicamentos de Ervas Chinesas/farmacologia
Feminino
Imunidade Celular/efeitos dos fármacos
Imunidade Humoral/efeitos dos fármacos
Imunogenicidade da Vacina/efeitos dos fármacos
Técnicas In Vitro
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
Camundongos Endogâmicos ICR
Ovalbumina/administração & dosagem
Ovalbumina/imunologia
Plantas Medicinais/química
Polissacarídeos/administração & dosagem
Polissacarídeos/isolamento & purificação
Solubilidade
Linfócitos T Reguladores/efeitos dos fármacos
Linfócitos T Reguladores/imunologia
Receptor 4 Toll-Like/metabolismo
Água
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Drugs, Chinese Herbal); 0 (Polysaccharides); 0 (Tlr4 protein, mouse); 0 (Toll-Like Receptor 4); 059QF0KO0R (Water); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191356


  9 / 4224 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223395
[Au] Autor:Takebe T; Sakamoto K; Higami Y; Harada Y
[Ad] Endereço:Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan; Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba,
[Ti] Título:A novel mouse model for tracking the fate of CXCR5-expressing T cells.
[So] Source:Biochem Biophys Res Commun;495(2):1642-1647, 2018 01 08.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The germinal center (GC) reaction, a critical process in the humoral immune response, requires follicular helper T (Tfh) cells. Tfh cells express the master transcription factor Bcl6 and chemokine receptor CXCR5, which enable them to migrate from the T cell zone to B cell follicles and interact with GC B cells. However, CXCR5 is downregulated when Tfh cells become memory cells. Therefore, it is difficult to track Tfh cells continuously in vivo. In this study, we generated a mouse strain, Cxcr5 R26 , in which the fluorescent protein tdTomato is inducibly expressed in CXCR5 cells by tamoxifen administration. After the oral administration of tamoxifen, most Tfh cells in Peyer's patches (PP) from Cxcr5 R26 mice were tdTomato . To track antigen-specific Tfh cells in vivo, OVA-specific OT-II T cells derived from Cxcr5 R26 mice were transferred to wild-type mice, and the recipient mice were immunized with OVA followed by tamoxifen administration. CXCR5 T cells became tdTomato and were mainly located in B cell follicles and GC areas 8 days after immunization. Four weeks after immunization, tdTomato OT-II T cells migrated from B cell follicles to the T-B border area and T cell zone after CXCR5 downregulation and CCR7 upregulation. These results indicate that Cxcr5 R26 mice are a useful tool for studying the cell fate of differentiated Tfh cells in vivo and therefore have implications for the development of therapeutic strategies for infectious and autoimmune diseases.
[Mh] Termos MeSH primário: Receptores CXCR5/metabolismo
Linfócitos T Auxiliares-Indutores/imunologia
[Mh] Termos MeSH secundário: Transferência Adotiva
Animais
Linfócitos B/imunologia
Diferenciação Celular
Movimento Celular/imunologia
Centro Germinativo/citologia
Centro Germinativo/imunologia
Imunidade Humoral
Memória Imunológica
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Modelos Animais
Modelos Imunológicos
Ovalbumina/imunologia
Receptores CXCR5/genética
Linfócitos T Auxiliares-Indutores/citologia
Linfócitos T Auxiliares-Indutores/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Blr1 protein, mouse); 0 (Receptors, CXCR5); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  10 / 4224 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29304144
[Au] Autor:Davis CL; Wahid R; Toapanta FR; Simon JK; Sztein MB
[Ad] Endereço:Natural Science Division, Pepperdine University, Malibu, CA, United States of America.
[Ti] Título:A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
[So] Source:PLoS One;13(1):e0189571, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We refine and clinically parameterize a mathematical model of the humoral immune response against Shigella, a diarrheal bacteria that infects 80-165 million people and kills an estimated 600,000 people worldwide each year. Using Latin hypercube sampling and Monte Carlo simulations for parameter estimation, we fit our model to human immune data from two Shigella EcSf2a-2 vaccine trials and a rechallenge study in which antibody and B-cell responses against Shigella's lipopolysaccharide (LPS) and O-membrane proteins (OMP) were recorded. The clinically grounded model is used to mathematically investigate which key immune mechanisms and bacterial targets confer immunity against Shigella and to predict which humoral immune components should be elicited to create a protective vaccine against Shigella. The model offers insight into why the EcSf2a-2 vaccine had low efficacy and demonstrates that at a group level a humoral immune response induced by EcSf2a-2 vaccine or wild-type challenge against Shigella's LPS or OMP does not appear sufficient for protection. That is, the model predicts an uncontrolled infection of gut epithelial cells that is present across all best-fit model parameterizations when fit to EcSf2a-2 vaccine or wild-type challenge data. Using sensitivity analysis, we explore which model parameter values must be altered to prevent the destructive epithelial invasion by Shigella bacteria and identify four key parameter groups as potential vaccine targets or immune correlates: 1) the rate that Shigella migrates into the lamina propria or epithelium, 2) the rate that memory B cells (BM) differentiate into antibody-secreting cells (ASC), 3) the rate at which antibodies are produced by activated ASC, and 4) the Shigella-specific BM carrying capacity. This paper underscores the need for a multifaceted approach in ongoing efforts to design an effective Shigella vaccine.
[Mh] Termos MeSH primário: Modelos Imunológicos
Vacinas contra Shigella/imunologia
[Mh] Termos MeSH secundário: Anticorpos Antibacterianos/biossíntese
Linfócitos B/imunologia
Ensaios Clínicos como Assunto
Simulação por Computador
Desenho de Drogas
Disenteria Bacilar/imunologia
Disenteria Bacilar/microbiologia
Disenteria Bacilar/prevenção & controle
Interações Hospedeiro-Patógeno/imunologia
Seres Humanos
Imunidade Humoral
Conceitos Matemáticos
Método de Monte Carlo
Shigella/imunologia
Shigella/patogenicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Shigella Vaccines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180210
[Lr] Data última revisão:
180210
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189571



página 1 de 423 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde